RT Journal Article
SR Electronic
T1 A new and efficient enrichment method for metagenomic sequencing of monkeypox virus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.29.22278145
DO 10.1101/2022.07.29.22278145
A1 Aja-Macaya, Pablo
A1 Rumbo-Feal, Soraya
A1 Poza, Margarita
A1 Cañizares, Angelina
A1 Vallejo, Juan A.
A1 Bou, Germán
YR 2022
UL http://medrxiv.org/content/early/2022/07/31/2022.07.29.22278145.abstract
AB Background The methodology described in previous literature for monkeypox virus (MPXV) sequencing shows low efficiency when using metagenomic approaches. The aim of the present study was to evaluate a new fine-tuned method for extraction and enrichment of genomic MPXV DNA using clinical samples and to compare it to a non-enrichment metagenomic approach.Results A new procedure that allows sample enrichment in MPXV DNA, avoiding wasting the sequencing quota in human DNA, was designed. This procedure consisted of host DNA depletion using a saponin/NaCl combination treatment and DNase. After typical quality control, samples using the enrichment method contained around 98 % of reads not classified as human DNA, while the non-enrichment protocol showed around 5-10 %. When reads not belonging to Orthopoxvirus were removed, enriched samples kept about 50 % of the original read counts, while non-enriched ones kept only 2-7 %.Conclusions Results showed a very significant improvement in sequencing efficiency, increasing the number of reads belonging to MPXV, the depth of coverage and the trustworthiness of the consensus sequences. This, in turn, would allow for more samples to be included in a single cartridge, reducing costs and time to diagnosis, which can be very important factors when dealing with a contagious disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by a grant from the SERGAS-Galician Healthcare Service (Program Innova Saude) to GB, by CIBERINFEC and also by Instituto de Salud Carlos III (ISCIII) through the projects PI20/00413 to MP and PI21/00704 to GB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research ethics committee of A Coruna - Ferrol (CEI, SERGAS) gave ethical approval for this work. The research ethics committee of A Coruna - Ferrol (Galicia, Spain) states that this study does not require ethical oversight. The obtained information comes from pathogenic organisms, not from the patient's clinical data. Neither the Spanish legislation for data protection and biomedical investigation, nor the European one, indicate that this study has to go through the revision of an ethics committee. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsITRsInverted terminal repeatsSNPsSingle nucleotide polymorphismshMPXHuman monkeypoxMPXVMonkeypox virus